Patent Covers Use of Plasma Gelsolin to Treat Multiple Sclerosis and to Diagnose Neurologic Diseases

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – March 4, 2013) BioAegis Therapeutics announced today that broad US patent protection for plasma gelsolin to treat Multiple Sclerosis (MS) and to diagnosis neurological disease. MS affects approximately 400,000 people in the US and 2.5 million worldwide and has enormous unmet need, despite recent product entries. In the US, prevalence estimates are approximately 90 per 100,000 population. MS symptoms can start anywhere between 10 and 80 years of age, but onset is usually between 20 and 40 years, with a mean of 32 years. According to a global study conducted by the World Health Organization, Neurological disorders are responsible for 8 out of 10 disorders in the 3 highest disability classes.


BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – March 1, 2013) BioAegis Therapeutics announced today that it has opened a research laboratory facility at the NJ Commercialization Center of Innovative Technology in North Brunswick, New Jersey.


Plans Phase 2b/3 Trial for Biologic in Prevention of Organ Dysfunction in ICU

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – February 7, 2013) BioAegis Therapeutics announced today that it completed it’s initial $3MM convertible note round to fund the companies operating activites in its effort to commercialize groundbreaking discoveries as to plasma gelsolin’s (pGSN) biological role in inflammation and infection. pGSN is the 4th most abundant protein in plasma and is highly conserved. Its depletion is highly predictive of adverse outcomes while its repletion in numerous animal models has been shown to prevent morbidity and mortality.


Advisors Engaged to Advance Biomarker-Driven Clinical Program

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – January 15, 2013) BioAegis Therapeutics announced that it has assembled a Critical Care Clinical Advisory Board comprised of world-recognized, highly experienced key opinion leaders. Initial members are:
Derek Angus, M.D., Professor and Chair, Critical Care Medicine and Professor, Medicine and Health Policy and Management, University of Pittsburgh School of Medicine
Atul Malhotra, M.D.,Associate Professor of Medicine, Harvard Medical School. Secretary-
Treasurer American Thoracic Society (2015-16 President)
Steven Opal, M.D.. Professor of Medicine, Brown University School of Medicine; Chief, Infectious Disease Division, Memorial Hospital of RI
B. Taylor Thompson, M.D., Professor of Medicine, Harvard Medical School; Director, Medical Intensive Care Unit, Massachusetts General Hospital


BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 10, 2012) Pursuant to the terms of the agreement with the Brigham and Women’s Hospital previously announced on May 11, 2011, BioAegis Therapeutics elected to exercise its option into an exclusive license to recombinant human plasma gelsolin technology.